PUMA BIOTECHNOLOGY, INC. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on February 27, 2018, reporting an event that occurred on February 23, 2018. The filing concerns the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation.
Material Changes
On February 23, 2018, Michael P. Miller was appointed to the Board of Directors. Mr. Miller brings significant experience in the life sciences industry, having previously served as Executive Vice President U.S. Commercial at Jazz Pharmaceuticals plc and in senior commercial roles at Vivus, Inc., Genentech, Inc., Connetics Corporation, ALZA Corporation, and Syntex Corporation.
Compensation and Governance Details
- Term: Expires at the 2018 Annual Meeting of Stockholders or until a successor is elected.
- Cash Compensation: Annual cash retainer of $50,000, paid in four quarterly installments of $12,500.
- Equity Compensation: Granted an option to purchase 17,626 shares of common stock with an approximate value of $700,000.
- Option Terms: Exercise price of $68.25 per share. Vesting schedule includes one-third on the first anniversary, followed by monthly vesting of 1/36th thereafter.
- Indemnification: The Company entered into a standard indemnification agreement with Mr. Miller.
Outlook and Risks
The filing does not contain guidance, outlook, or specific risk factors beyond the standard indemnification provisions. There are no reportable transactions or understandings between Mr. Miller and other persons under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the current stock price relative to the $68.25 exercise price of the granted options.
- Review the Company's non-employee director compensation program for consistency with peer biotechnology firms.
- Confirm the vesting schedule details in the definitive option agreement.
- Check for any subsequent filings regarding the 2018 Annual Meeting of Stockholders.